DAE HWA PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9,850 KRW | -1.40% |
|
+0.72% | +5.01% |
| Sales 2018 | 110B 79.96M | Sales 2019 | 115B 83.21M | Capitalization | 223B 162M |
|---|---|---|---|---|---|
| Net income 2018 | 6.65B 4.83M | Net income 2019 | 10.54B 7.65M | EV / Sales 2018 | 3.44 x |
| Net Debt 2018 | 28.81B 20.91M | Net Debt 2019 | 39.64B 28.78M | EV / Sales 2019 | 2.29 x |
| P/E ratio 2018 |
52.7
x | P/E ratio 2019 |
21.3
x | Employees | 308 |
| Yield 2018 |
0.76% | Yield 2019 |
1.17% | Free-Float | 64.95% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.40% | ||
| 1 week | +0.72% | ||
| Current month | +2.71% | ||
| 1 month | -2.96% | ||
| 3 months | -24.06% | ||
| 6 months | +7.42% | ||
| Current year | +5.01% |
1 week
9 660.00
10 130.00
1 month
9 570.0010 490.00
Current year
8 680.0013 670.00
1 year
7 390.0015 980.00
3 years
5 940.0015 980.00
5 years
5 820.0023 000.00
10 years
5 820.0059 700.00
| Managers | Title | Age | Since |
|---|---|---|---|
Byung-Tae Noh
CEO | Chief Executive Officer | 62 | 85-12-14 |
Eun-Seok Kim
CEO | Chief Executive Officer | 48 | 08-01-31 |
Jae-Seong Na
DFI | Director of Finance/CFO | 55 | 93-01-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Eun-Seok Kim
CEO | Chief Executive Officer | 48 | 08-01-31 |
Byung-Tae Noh
CEO | Chief Executive Officer | 62 | 85-12-14 |
Sang-Tae Lee
BRD | Director/Board Member | 59 | 89-02-28 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-10 | 9,850 | -1.40% | 43,216 |
| 24-06-07 | 9,990 | -0.30% | 51,821 |
| 24-06-05 | 10,020 | +2.56% | 72,206 |
| 24-06-04 | 9,770 | -0.10% | 33,066 |
End-of-day quote Korea S.E., June 09, 2024
More quotes
DAE HWA PHARM CO.,LTD. is a Korea-based company engaged in the manufacture of pharmaceuticals. The Companyâs products include skeletal muscle relaxants, gastro-intestinal drugs, corticosteroids, antihistamines, cardiovascular drugs, drugs for liver diseases, vitamins, tonics, antibiotics, injections, topical drugs, anti-inflammatory enzymes, analgesics, antipyretics, plaster, cough suppressants, expectorants and mucolytics, drugs for hemorrhoid disease and other prescription drugs, as well as over-the-counter (OTC) drugs. The Company distributes its products within domestic market and to overseas markets. On August 22, 2013, it acquired a certain shares of a Korea-based company, which is mainly engaged in the manufacture of medicine raw materials and development of medical devices. After the transaction, the Company held a 100% stake of the Korea-based company.
Sector
Pharmaceuticals
Calendar
2024-08-08
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +5.01% | 126M | |
| +19.78% | 80.29B | |
| +15.04% | 9.2B | |
| -18.33% | 4.67B | |
| +43.39% | 4.49B | |
| +13.95% | 4.27B | |
| +10.80% | 2.25B | |
| -28.40% | 2.13B | |
| +15.93% | 2.1B | |
| -43.17% | 1.78B |
- Stock Market
- Equities
- A067080 Stock
